(234 days)
Not Found
No
The description focuses on standard chemical reaction measurements and data processing, with no mention of AI or ML.
No
The device is an in vitro diagnostic (IVD) system used for quantitative determination of constituents in blood and other fluids, which aids in diagnosis and treatment, but does not directly provide therapy.
Yes
The "Intended Use / Indications for Use" section explicitly states that the ACE Axcel Clinical Chemistry System is "intended for in vitro diagnostic use" and that its measurements are "used in the diagnosis and treatment" of various diseases.
No
The device description explicitly states that the ACE Axcel Clinical Chemistry System consists of two major components: the chemistry instrument (hardware that performs measurements) and an integrated Panel PC (which includes software). This indicates it is a system with both hardware and software components, not a software-only device.
Yes, this device is an IVD (In Vitro Diagnostic).
Here's why:
- Explicit Statement: The "Intended Use / Indications for Use" section explicitly states: "The ACE Axcel Clinical Chemistry System is an automated, discrete, bench-top, random access analyzer that is intended for in vitro diagnostic use in the quantitative determination of constituents in blood and other fluids."
- Reagent Intended Use: The descriptions for the ACE Alkaline Phosphatase Reagent, ACE Amylase Reagent, and ACE LDH-L Reagent all state they are intended for quantitative determination of substances in serum using the system and conclude with "For in vitro diagnostic use only."
- Purpose: The system and reagents are used to measure specific substances (alkaline phosphatase, amylase, lactate dehydrogenase) in biological samples (serum) to aid in the diagnosis and treatment of various diseases. This is the core function of an in vitro diagnostic device.
- Care Setting: The intended user/care setting is clinical laboratories or physician office laboratories, which are typical environments for performing in vitro diagnostic testing.
N/A
Intended Use / Indications for Use
The ACE Axcel Clinical Chemistry System is an automated, discrete, bench-top, random access analyzer that is intended for in vitro diagnostic use in the quantitative determination of constituents in blood and other fluids.
The ACE Alkaline Phosphatase Reagent is intended for the quantitative determination of alkaline phosphatase activity in serum using the ACE Axcel Clinical Chemistry System. Measurements of alkaline phosphatase are used in the diagnosis and treatment of liver, bone, parathyroid, and intestinal diseases. This test is intended for use in clinical laboratories or physician office laboratories. For in vitro diagnostic use only.
The ACE Amylase Reagent is intended for the quantitative determination of α-amylase activity in serum using the ACE Axcel Clinical Chemistry System. Amylase measurements are used primarily for the diagnosis and treatment of pancreatitis (inflammation of the pancreas). This test is intended for use in clinical laboratories or physician office laboratories. For in vitro diagnostic use only.
The ACE LDH-L Reagent is intended for the quantitative determination of lactate dehydrogenase activity in serum using the ACE Axcel Clinical Chemistry System. Lactate dehydrogenase measurements are used in the diagnosis and treatment of liver diseases such as acute viral hepatitis, cirrhosis, and metastatic carcinoma of the liver, cardiac diseases such as myocardial infarction and tumors of the lung or kidneys. This test is intended for use in physician office laboratories or clinical laboratories. For in vitro diagnostic use only.
Product codes (comma separated list FDA assigned to the subject device)
JJE, CJE, CIJ, CFJ
Device Description
The ACE Axcel Clinical Chemistry System consists of two major components, the chemistry instrument and an integrated Panel PC. The instrument accepts the physical patient samples, performs the appropriate optical or potentiometric measurements on those samples and communicates that data to an integral Panel PC. The Panel PC uses keyboard or touch screen input to manually enter a variety of data, control and accept data from the instrument, manage and maintain system information and generate reports relative to patient status and instrument performance. The Panel PC also allows remote download of patient requisitions and upload of patient results via a standard interface.
In the ACE Alkaline Phosphatase Reagent assay, alkaline phosphatase in serum catalyzes the hydrolysis of colorless p-nitrophenyl phosphate to p-nitrophenol and inorganic phosphate. In an alkaline solution (pH 10.5), p-nitrophenol is in the phenoxide form and has a strong absorbance at 408 nm. The rate of increase in absorbance, monitored bichromatically at 408 nm/486 nm, is directly proportional to the alkaline phosphatase activity in the sample.
In the ACE AST Reagent assay, a-amylase hydrolyzes the 2-chloro-p-nitrophenyl-a-D-maltotrioside substrate to release 2-chloro-p-nitrophenol and form 2-chloro-p- nitrophenyl-a-D-maltoside, maltotriose and glucose. The rate of increase in absorbance, monitored bichromatically at 408 nm/ 647 nm, is directly proportional to the a-amylase activity in the sample.
In the ACE LDH-L Reagent assay, lactate dehydrogenase catalyzes the conversion of L-lactate to pyruvate. Nicotinamide adenine dinucleotide (NAD+) acts as an acceptor for the hydrogen ions released from the L-lactate and is converted to reduced nicotinamide adenine dinucleotide (NADH). NADH absorbs strongly at 340 nm whereas NAD+ does not. Therefore, the rate of conversion of NAD+ to NADH can be determined by monitoring the increase in absorbance bichromatically at 340 nm/647 nm. This rate of conversion from NAD+ to NADH is directly proportional to the lactate dehydrogenase activity in the sample.
The following is a description of the major features of the ACE Axcel Clinical Chemistry System:
System throughput is approximately 160 test results per hour for routine, single reagent chemistries. System throughput will be higher when the test workload includes ISE's. The instrument has a capacity of 40 reagent containers on board. A reagent cooling system maintains the reagents at 12°C during instrument operation. Reagent containers are identified by computer coded labels to simplify system operation. All reagents in the system must include an identification label on the container.
Sample and reagent sensing notify the operator of a depleted condition during operation. The system performs analysis at a reaction temperature of 37°C. An electrolyte subsystem capable of measuring sodium, potassium and chloride concentrations is included. Primary draw tubes may be introduced one at a time into the system for closed tube sampling. Positive tube identification can be achieved with an optional barcode scanner. An aliquot volume sufficient for all tests ordered is transferred and stored and the closed tube is returned to the user. Sample cups are introduced to the system one at a time or by sample ring segment. Disposable cuvettes are loaded in bulk and then automatically injected as needed by a cuvette hopper system. The ACE Axcel clinical chemistry optical system is capable of monitoring a maximum of 48 cuvettes at one time. The absorbance optical system is capable of absorbance measurements in a linear range of 0.0 to 2.0 absorbance units (at 0.67 cm pathlength). Sixteen wavelengths are measured simultaneously using a photodiode array. The ACE Alkaline Phosphatase Reagent is composed of two reagent bottles (Buffer and Substrate Reagent). The reagents contain AMP Buffer (pH 10.45), magnesium acetate, p-nitrophenyl phosphate.
The ACE Amylase Reagent is composed of a single reagent bottle. The reagents contain 2-chloro-p-nitrophenyl-α-D-maltotrioside, sodium chloride, calcium acetate, potassium thiocyanate and MES buffer (pH 6.0).
The ACE LDH-L Reagent is composed of two reagent bottles (Substrate and Coenzyme Reagent). The reagents contain L-lactic acid and nicotinamide adenine dinucleotide.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
clinical laboratories or physician office laboratories.
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Performance data for the Alfa Wassermann ACE Reagents run on the Alfa Wassermann ACE Axcel Clinical Chemistry System included precision, accuracy, and detection limit data.
ACE Alkaline Phosphatase Reagent
Precision: In testing conducted at four alkaline phosphatase levels for 22 days, the within-run CV ranged from 1.3 to 3.2%, and total CV ranged from 2.8 to 4.7%. In precision studies at three separate Physician Office Laboratory (POL) sites over 5 days, the within-run CV ranged from 1.0 to 4.8% and total CV ranged from 2.0 to 5.7%.
Accuracy: In the correlation study, 112 samples with alkaline phosphatase values ranging from 12 to 1363 U/L were assayed on the Alfa Wassermann ACE Axcel Clinical Chemistry System (y) and the Alfa Wassermann ACE Clinical Chemistry System (x). Least squares regression analysis yielded a correlation coefficient of 0.9997, a standard error estimate of 5.1, a confidence interval slope of 0.978 to 0.987, and a confidence interval intercept of -0.5 to 1.8. In patient correlation studies at three separate POL sites, using the Alfa Wassermann ACE Axcel Clinical Chemistry System (y) and the Alfa Wassermann ACE Clinical Chemistry System (x), least-squares regression analysis yielded correlation coefficients of 0.9957 to 0.9998, standard error estimates of 6.0 to 25.3, confidence interval slopes of 0.966 to 1.063, and a confidence interval intercepts of -4.0 to 14.5.
Detection limit: The detection limit was 1.3 U/L.
ACE Amylase Reagent
Precision: In testing conducted at four amylase levels for 22 days, the within-run CV ranged from 1.5 to 3.4%, and total CV ranged from 1.7 to 3.6%. In precision studies at three separate Physician Office Laboratory (POL) sites 5 days, the within-run CV ranged from 0.8 to 4.7% and total CV ranged from 0.9 to 5.7%.
Accuracy: In the correlation study, 111 samples with amylase values ranging from 11 to 1650 U/L were assayed on the Alfa Wassermann ACE Axcel Clinical Chemistry System (y) and the Alfa Wassermann ACE Clinical Chemistry System (x). Least squares regression analysis yielded a correlation coefficient of 0.9997, a standard error estimate of 6.5. a confidence interval slope of 0.953 to 0.962. and a confidence interval intercept of -0.7 to 2.0. In patient correlation studies at three separate POL sites, using the Alfa Wassermann ACE Axcel Clinical Chemistry System (y) and the Alfa Wassermann ACE Clinical Chemistry System (x), least-squares regression analysis yielded correlation coefficients of 0.9985 to 1.0000, standard error estimates of 3.4 to 22.3, confidence interval slopes of 0.968 to 1.022, and a confidence interval intercepts of -7.7 to 6.7.
Detection limit: The detection limit was 8.5 U/L.
ACE LDH-L Reagent
Precision: In testing conducted at four LDH levels for 22 days, the within-run CV ranged from 1.6 to 3.1%, and total CV ranged from 2.3 to 4.6%. In precision studies at three separate Physician Office Laboratory (POL) sites over 5 days, the within-run CV ranged from 1.1 to 3.0% and total CV ranged from 1.7 to 3.3%.
Accuracy: In the correlation study, 121 samples with LDH values ranging from 22 to 829 U/L were assayed on the Alfa Wassermann ACE Axcel Clinical Chemistry System (y) and the Alfa Wassermann ACE Clinical Chemistry System (x). Least squares regression analysis yielded a correlation coefficient of 0.9986, a standard error estimate of 7.5, a confidence interval slope of 1.036 to 1.056, and a confidence interval intercept of 2.8 to 7.0. In patient correlation studies at three separate POL sites, using the Alfa Wassermann ACE Axcel Clinical Chemistry System (y) and the Alfa Wassermann ACE Clinical Chemistry System (x), least-squares regression analysis yielded correlation coefficients of 0.9983 to 0.9993, standard error estimates of 6.3 to 13.1, confidence interval slopes of 0.995 to 1.052, and a confidence interval intercepts of -8.5 to 6.2.
Detection limit: The detection limit was 8.3 U/L.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 862.1050 Alkaline phosphatase or isoenzymes test system.
(a)
Identification. An alkaline phosphatase or isoenzymes test system is a device intended to measure alkaline phosphatase or its isoenzymes (a group of enzymes with similar biological activity) in serum or plasma. Measurements of alkaline phosphatase or its isoenzymes are used in the diagnosis and treatment of liver, bone, parathyroid, and intestinal diseases.(b)
Classification. Class II.
0
Image /page/0/Picture/0 description: The image shows the text "Page 40,". The text is in bold font and is located in the top left corner of the image. There are some other markings on the right side of the image.
Attachment 4
: :
JUL 1 2 2012
New 510(k) Summary
Alkaline Phosphatase, Amylase and LDH-L Reagents on the ACE Axcel Clinical Chemistry System
510(k) SUMMARY
| 510(k) Owner: | Alfa Wassermann Diagnostic Technologies, LLC
4 Henderson Drive
West Caldwell, NJ 07006 | | |
|------------------------|----------------------------------------------------------------------------------------------|---------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------|
| | Contact: | Hyman Katz, Ph.D.
Phone: 973-852-0158
Fax: 973-852-0237 | |
| Date Summary Prepared: | April 12, 2012 | | |
| Device: | Trade Name:
System | | ACE Axcel Clinical Chemistry |
| | Classification: | | Class 1 |
| | Common/Classification Name: | | Analyzer, Chemistry (Photometric,
Discrete), For Clinical Use
(21 C. F.R. § 862.2610)
Product Code JJE |
| | Trade Name:
Reagent | | ACE Alkaline Phosphatase |
| | Classification: | | Class 2 |
| | Common/Classification Name: | | Nitrophenylphosphate, Alkaline
Phosphatase Or Isoenzymes
(21 C. F.R. § 862.1050)
Product Code CJE |
| | Trade Name: | | ACE Amylase Reagent |
| | Classification: | | Class 2 |
| | Common/Classification Name: | | Saccharogenic, Amylase
(21 C. F.R. § 862.1070)
Product Code CIJ |
1
.
:
. .
| Trade Name: | ACE LDH-L Reagent |
|---|---|
| Classification: | Class 2 |
| Common/Classification Name: | NAD Reduction/NADH Oxidation, |
| Lactate Dehydrogenase | |
| (21 C. F.R. § 862.1440) | |
| Product Code CFJ | |
| Predicate | |
| Devices: | Manufacturer for analyzer/reagent system predicate: |
| Alfa Wassermann ACE Clinical Chemistry System | |
| ACE Reagents (K931786) | |
| Device | |
| Descriptions: | The ACE Axcel Clinical Chemistry System consists of two major |
| components, the chemistry instrument and an integrated Panel PC. The | |
| instrument accepts the physical patient samples, performs the | |
| appropriate optical or potentiometric measurements on those samples | |
| and communicates that data to an integral Panel PC. The Panel PC uses | |
| keyboard or touch screen input to manually enter a variety of data, | |
| control and accept data from the instrument, manage and maintain | |
| system information and generate reports relative to patient status and | |
| instrument performance. The Panel PC also allows remote download of | |
| patient requisitions and upload of patient results via a standard | |
| interface. |
In the ACE Alkaline Phosphatase Reagent assay, alkaline phosphatase
in serum catalyzes the hydrolysis of colorless p-nitrophenyl phosphate
to p-nitrophenol and inorganic phosphate. In an alkaline solution (pH
10.5), p-nitrophenol is in the phenoxide form and has a strong
absorbance at 408 nm. The rate of increase in absorbance, monitored
bichromatically at 408 nm/486 nm, is directly proportional to the
alkaline phosphatase activity in the sample.
In the ACE AST Reagent assay, a-amylase hydrolyzes the 2-chloro-p-
nitrophenyl-a-D-maltotrioside substrate to release 2-chloro-p-
nitrophenol and form 2-chloro-p- nitrophenyl-a-D-maltoside,
maltotriose and glucose. The rate of increase in absorbance, monitored
bichromatically at 408 nm/ 647 nm, is directly proportional to the a-
amylase activity in the sample.
In the ACE LDH-L Reagent assay, lactate dehydrogenase catalyzes the
conversion of L-lactate to pyruvate. Nicotinamide adenine dinucleotide
(NAD+) acts as an acceptor for the hydrogen ions released from the L-
lactate and is converted to reduced nicotinamide adenine dinucleotide
(NADH). NADH absorbs strongly at 340 nm whereas NAD+ does not.
Therefore, the rate of conversion of NAD+ to NADH can be determined |
| Intended Use: | by monitoring the increase in absorbance bichromatically at 340
nm/647 nm. This rate of conversion from NAD+ to NADH is directly
proportional to the lactate dehydrogenase activity in the sample.
Indications for Use: |
| | The ACE Axcel Clinical Chemistry System is an automated, discrete,
bench-top, random access analyzer that is intended for in vitro
diagnostic use in the quantitative determination of constituents in blood
and other fluids. |
| | The ACE Alkaline Phosphatase Reagent is intended for the quantitative
determination of alkaline phosphatase activity in serum using the ACE
Axcel Clinical Chemistry System. Measurements of alkaline
phosphatase are used in the diagnosis and treatment of liver, bone,
parathyroid, and intestinal diseases. This test is intended for use in
clinical laboratories or physician office laboratories. For in vitro
diagnostic use only. |
| | The ACE Amylase Reagent is intended for the quantitative
determination of α-amylase activity in serum using the ACE Axcel
Clinical Chemistry System. Amylase measurements are used primarily
for the diagnosis and treatment of pancreatitis (inflammation of the
pancreas). This test is intended for use in clinical laboratories or
physician office laboratories. For in vitro diagnostic use only. |
| | The ACE LDH-L Reagent is intended for the quantitative
determination of lactate dehydrogenase activity in serum using the
ACE Axcel Clinical Chemistry System. Lactate dehydrogenase
measurements are used in the diagnosis and treatment of liver diseases
such as acute viral hepatitis, cirrhosis, and metastatic carcinoma of the
liver, cardiac diseases such as myocardial infarction and tumors of the
lung or kidneys. This test is intended for use in physician office
laboratories or clinical laboratories. For in vitro diagnostic use only. |
| Technological
Characteristics: | The following is a description of the major features of the ACE Axcel
Clinical Chemistry System: |
| | System throughput is approximately 160 test results per hour for
routine, single reagent chemistries. System throughput will be
higher when the test workload includes ISE's. The instrument has a capacity of 40 reagent containers on board. A reagent cooling system maintains the reagents at 12°C during
instrument operation. Reagent containers are identified by computer coded labels to
simplify system operation. All reagents in the system must |
| | include an identification label on the container. |
| Sample and reagent sensing notify the operator of a depleted condition during operation. The system performs analysis at a reaction temperature of 37°C. An electrolyte subsystem capable of measuring sodium, potassium and chloride concentrations is included. Primary draw tubes may be introduced one at a time into the system for closed tube sampling. Positive tube identification can be achieved with an optional barcode scanner. An aliquot volume sufficient for all tests ordered is transferred and stored and the closed tube is returned to the user. Sample cups are introduced to the system one at a time or by sample ring segment. Disposable cuvettes are loaded in bulk and then automatically injected as needed by a cuvette hopper system. The ACE Axcel clinical chemistry optical system is capable of monitoring a maximum of 48 cuvettes at one time. The absorbance optical system is capable of absorbance measurements in a linear range of 0.0 to 2.0 absorbance units (at 0.67 cm pathlength). Sixteen wavelengths are measured simultaneously using a photodiode array. The ACE Alkaline Phosphatase Reagent is composed of two reagent bottles (Buffer and Substrate Reagent). The reagents contain AMP Buffer (pH 10.45), magnesium acetate, p-nitrophenyl phosphate.
The ACE Amylase Reagent is composed of a single reagent bottle. The reagents contain 2-chloro-p-nitrophenyl-α-D-maltotrioside, sodium chloride, calcium acetate, potassium thiocyanate and MES buffer (pH 6.0).
The ACE LDH-L Reagent is composed of two reagent bottles (Substrate and Coenzyme Reagent). The reagents contain L-lactic acid and nicotinamide adenine dinucleotide. | |
| Performance Data: | Performance data for the Alfa Wassermann ACE Reagents run on the Alfa Wassermann ACE Axcel Clinical Chemistry System included precision, accuracy, and detection limit data.
ACE Alkaline Phosphatase Reagent
Precision: In testing conducted at four alkaline phosphatase levels for 22 days, the within-run CV ranged from 1.3 to 3.2%, and total CV ranged from 2.8 to 4.7%. In precision studies at three separate Physician Office Laboratory (POL) sites over 5 days, the within-run CV ranged from 1.0 to 4.8% and total CV ranged from 2.0 to 5.7%. |
.
.
.
:
:
:
・
·
:
.
:
.
2
·
:
·
3
:
.
:
and the same of the same of the same
.
:
.
:
.
,
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
4
Accuracy: In the correlation study, 112 samples with alkaline phosphatase values ranging from 12 to 1363 U/L were assayed on the Alfa Wassermann ACE Axcel Clinical Chemistry System (y) and the Alfa Wassermann ACE Clinical Chemistry System (x). Least squares regression analysis vielded a correlation coefficient of 0.9997, a standard error estimate of 5.1, a confidence interval slope of 0.978 to 0.987, and a confidence interval intercept of -0.5 to 1.8. In patient correlation studies at three separate POL sites, using the Alfa Wassermann ACE Axcel Clinical Chemistry System (y) and the Alfa Wassermann ACE Clinical Chemistry System (x), least-squares regression analysis vielded correlation coefficients of 0.9957 to 0.9998, standard error estimates of 6.0 to 25.3, confidence interval slopes of 0.966 to 1.063, and a confidence interval intercepts of -4.0 to 14.5.
Detection limit: The detection limit was 1.3 U/L.
ACE Amylase Reagent
Precision: In testing conducted at four amylase levels for 22 days, the within-run CV ranged from 1.5 to 3.4%, and total CV ranged from 1.7 to 3.6%. In precision studies at three separate Physician Office Laboratory (POL) sites 5 days, the within-run CV ranged from 0.8 to 4.7% and total CV ranged from 0.9 to 5.7%.
Accuracy: In the correlation study, 111 samples with amylase values ranging from 11 to 1650 U/L were assayed on the Alfa Wassermann ACE Axcel Clinical Chemistry System (y) and the Alfa Wassermann ACE Clinical Chemistry System (x). Least squares regression analysis yielded a correlation coefficient of 0.9997, a standard error estimate of 6.5. a confidence interval slope of 0.953 to 0.962. and a confidence interval intercept of -0.7 to 2.0. In patient correlation studies at three separate POL sites, using the Alfa Wassermann ACE Axcel Clinical Chemistry System (y) and the Alfa Wassermann ACE Clinical Chemistry System (x), least-squares regression analysis vielded correlation coefficients of 0.9985 to 1.0000, standard error estimates of 3.4 to 22.3, confidence interval slopes of 0.968 to 1.022, and a confidence interval intercepts of -7.7 to 6.7.
Detection limit: The detection limit was 8.5 U/L.
ACE LDH-L Reagent
Precision: In testing conducted at four LDH levels for 22 days, the within-run CV ranged from 1.6 to 3.1%, and total CV ranged from 2.3 to 4.6%. In precision studies at three separate Physician Office Laboratory (POL) sites over 5 days, the within-run CV ranged from 1.1 to 3.0% and total CV ranged from 1.7 to 3.3%.
5
the submit the state of the states of the states and
.
.
. . . . . .
| | Accuracy: In the correlation study, 121 samples with LDH values
ranging from 22 to 829 U/L were assayed on the Alfa Wassermann
ACE Axcel Clinical Chemistry System (y) and the Alfa Wassermann
ACE Clinical Chemistry System (x). Least squares regression analysis
yielded a correlation coefficient of 0.9986, a standard error estimate of
7.5, a confidence interval slope of 1.036 to 1.056, and a confidence
interval intercept of 2.8 to 7.0. In patient correlation studies at three
separate POL sites, using the Alfa Wassermann ACE Axcel Clinical
Chemistry System (y) and the Alfa Wassermann ACE Clinical
Chemistry System (x), least-squares regression analysis yielded
correlation coefficients of 0.9983 to 0.9993, standard error estimates of
6.3 to 13.1, confidence interval slopes of 0.995 to 1.052, and a
confidence interval intercepts of -8.5 to 6.2.
Detection limit: The detection limit was 8.3 U/L. |
|--------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Conclusions: | Based on the foregoing data, the device is safe and effective. These
data also indicate substantial equivalence to the predicate device. |
and the contraction of the comments of the comments of the comments of the contraction of the contraction of the contribution of the contribution of the contribution of the c
.
:
6
DEPARTMENT OF HEALTH & HUMAN SERVICES
Image /page/6/Picture/1 description: The image shows the seal of the Department of Health & Human Services (HHS) of the United States. The seal features the department's name arranged in a circular pattern around the outer edge. Inside the circle is a stylized image of an eagle, which is a common symbol of the United States.
10903 New Hampshire Avenue Silver Spring, MD 20993
Alfa Wasserman Diagnostic Technologies, .LLC c/o Hyman Katz, Ph.D. 4 Henderson Drive West Caldwell, NJ 07006
Re: K113436
Trade Name: ACE Alkaline Phosphatase Reagent ACE Amylase Reagent ACE LDH-L Reagent Regulation Number: 21 CFR §862.1050 Regulation Name: Alkaline phosphatase or isoenzymes test system Regulatory Class: Class II Product Codes: CJE, CIJ, CFJ Dated: June 7, 2012 Received: June 8, 2012
Dear Dr Katz:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).
JUL 12 2012
7
Page 2
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please 11 you desire specific advice for your cic Device Evaluation and Safety at (301) 796-5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21) prease note the regulation official crearding postmarket surveillance, please contact CDRH3 CITY at 607.97). For questions regarding postmarket Surveillance at (301) Office of but romance and 22cline the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/Medical
CITY art 005), product go to hear in the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance ...
You may obtain other general information on your responsibilities under the Act from the Tou may octuril one. Benefal memational and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-5680 or at its Internet address http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm
Sincerely yours,
Courtney H. Lias, Ph.D. Director Division of Chemistry and Toxicology Devices Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health
Enclosure
8
Indications for Use
Device Name: ACE Alkaline Phosphatase Reagent
The ACE Alkaline Phosphatase Reagent is intended for the quantitative Indications for Use: determination of alkaline phosphatase activity in serum using the ACE Axcel Clinical Chemistry System. Measurements of alkaline phosphatase are used in the diagnosis and treatment of liver, bone, parathyroid, and intestinal diseases. This test is intended for use in clinical laboratories or physician office laboratories. For in vitro diagnostic use only.
Device Name: ACE Amylase Reagent
The ACE Amylase Reagent is intended for the quantitative determination Indications for Use: of a-amylase activity in serum using the ACE Axcel Clinical Chemistry System. Amylase measurements are used primarily for the diagnosis and treatment of pancreatitis (inflammation of the pancreas). This test is intended for use in clinical laboratories or physician office laboratories. For in vitro diagnostic use only.
Device Name: ACE LDH-L Reagent
Indications for Use:
The ACE LDH-L Reagent is intended for the quantitative determination of lactate dehydrogenase activity in serum using the ACE Axcel Clinical Chemistry System. Lactate dehydrogenase measurements are used in the diagnosis and treatment of liver diseases such as acute viral hepatitis, cirrhosis, and metastatic carcinoma of the liver, cardiac diseases such as myocardial infarction and tumors of the lung or kidneys. This test is intended for use in clinical laboratories or physician office laboratories. For in vitro diagnostic use only.
Prescription Use X (21 CFR Part 801 Subpart D) AND/OR
Over-The-Counter Use. (21 CFR Part 801 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE; CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)
Division Sign-Off Office of In Vitro Diagnostic Device Evaluation and Safety
510(k) K113436
Page 1 of 1